A Randomised, Double-blind, Active-controlled Study to Evaluate the Impact of Stepwise Withdrawal of Inhaled Corticosteroid Treatment in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) on Optimized Bronchodilator Therapy
Latest Information Update: 17 Dec 2021
At a glance
- Drugs Fluticasone propionate (Primary) ; Salmeterol (Primary) ; Tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms WISDOM
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 19 May 2021 Results of pooled analysis from six studies (TONADO 1-2, DYNAGITO, WISDOM, UPLIFT and TIOSPIR) comparing the time to all-cause mortality with LAMA/LABA/ICS versus LAMA+LABA in a population of patients with predominantly moderate-to-severe COPD and a predominantly lower exacerbation risk, presented at the 117th International Conference of the American Thoracic Society.
- 18 May 2016 Results (post hoc analysis, n = 262) assessing lung-function profile before and after the first moderate to severe exacerbation presented at the 112th International Conference of the American Thoracic Society.
- 18 May 2016 Results of a post hoc subgroup analysis (n=2296) presented at the 112th International Conference of the American Thoracic Society